Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28547018 | 0.83 | RXFP1 (0.74) | RXFP1ALDH1A1ADORA2BSMN1; SMN2PDE3A | |
| SCHEMBL17786242 | 0.80 | ALDH1A1 (1.00) | RXFP1ALDH1A1ADORA2BSMN1; SMN2TSHR | |
| SCHEMBL10966452 | 0.79 | RXFP1 (0.64) | RXFP1ALDH1A1ADORA2BSMN1; SMN2TSHR | |
| SCHEMBL1944405 | 0.79 | ADORA2B (1.00) | RXFP1ALDH1A1ADORA2BSMN1; SMN2TSHR | |
| SCHEMBL28538511 | 0.78 | RXFP1 (0.67) | RXFP1ALDH1A1ADORA2BSMN1; SMN2PDE3A | |
| SCHEMBL30810227 | 0.78 | RXFP1 (0.67) | RXFP1ALDH1A1ADORA2BSMN1; SMN2PDE3A | |
| SCHEMBL20030199 | 0.78 | ALDH1A1 (0.60) | RXFP1ALDH1A1ADORA2BSMN1; SMN2TSHR | |
| SCHEMBL7608305 | 0.77 | POLB (0.75) | RXFP1ALDH1A1ADORA2BSMN1; SMN2TSHR | |
| SCHEMBL30810226 | 0.76 | ADORA2B (0.61) | RXFP1ALDH1A1ADORA2BSMN1; SMN2TSHR | |
| SCHEMBL11380422 | 0.76 | ADORA2B (0.70) | RXFP1ALDH1A1ADORA2BSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506876-B1 | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use | G.D. SEARLE & CO. | 2003-01-14 | — | — | US | disclosed |
| EP-0804427-B1 | LTA4 HYDROLASE INHIBITORS | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1221441-A2 | LTA4 Hydrolase inhibitors | G.D. SEARLE & CO. (US) | 2002-07-10 | — | — | EP | disclosed |
| US-5723492-A | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use | G.D. SEARLE & CO. (US) | 1998-03-03 | — | — | US | disclosed |
| US-5719306-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0804427-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0786992-A2 | LTA 4? HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1997-08-06 | — | — | EP | disclosed |
| US-5585492-A | USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES WHICH ARE MEDIATED BY LTB4 PRODUCTION, SUCH AS PSORIASIS, ULCERATIVE COLITIS, IRRITABLE BOWEL DISEASE AND ASTHMA | G. D. SEARLE & CO. (US) | 1996-12-17 | — | — | US | disclosed |
| WO-1996010999-A2 | LTA4 HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |
| WO-1996011192-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |